Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINFALL: ramucirumab plus capecitabine/cisplatin versus placebo plus capecitabine/cisplatin in first-line metastatic gastric or gastroesophageal junction adenocarcinoma
2014-002240-40Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Ramucirumab + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Feb 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2014-002240-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002240-40.